JP3579355B2 - ヒトの乾癬を予防及び治療するための乾癬モデル動物 - Google Patents

ヒトの乾癬を予防及び治療するための乾癬モデル動物 Download PDF

Info

Publication number
JP3579355B2
JP3579355B2 JP2000586893A JP2000586893A JP3579355B2 JP 3579355 B2 JP3579355 B2 JP 3579355B2 JP 2000586893 A JP2000586893 A JP 2000586893A JP 2000586893 A JP2000586893 A JP 2000586893A JP 3579355 B2 JP3579355 B2 JP 3579355B2
Authority
JP
Japan
Prior art keywords
cells
host
mice
psoriasis
scid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000586893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531123A5 (cg-RX-API-DMAC7.html
JP2002531123A (ja
Inventor
エールハルト,ロルフ
ホン,ケネス
クイーン,キャリー
Original Assignee
プロテイン デザイン ラブス インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3579355(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by プロテイン デザイン ラブス インコーポレイティド filed Critical プロテイン デザイン ラブス インコーポレイティド
Publication of JP2002531123A publication Critical patent/JP2002531123A/ja
Application granted granted Critical
Publication of JP3579355B2 publication Critical patent/JP3579355B2/ja
Publication of JP2002531123A5 publication Critical patent/JP2002531123A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2000586893A 1998-12-09 1999-12-08 ヒトの乾癬を予防及び治療するための乾癬モデル動物 Expired - Fee Related JP3579355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11164298P 1998-12-09 1998-12-09
US60/111,642 1998-12-09
PCT/US1999/029123 WO2000034459A1 (en) 1998-12-09 1999-12-08 Animal model for psoriasis for the prevention and treatment of psoriasis in humans

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004145466A Division JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2002531123A JP2002531123A (ja) 2002-09-24
JP3579355B2 true JP3579355B2 (ja) 2004-10-20
JP2002531123A5 JP2002531123A5 (cg-RX-API-DMAC7.html) 2005-04-07

Family

ID=22339643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000586893A Expired - Fee Related JP3579355B2 (ja) 1998-12-09 1999-12-08 ヒトの乾癬を予防及び治療するための乾癬モデル動物
JP2004145466A Expired - Fee Related JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004145466A Expired - Fee Related JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Country Status (10)

Country Link
US (5) US6410824B1 (cg-RX-API-DMAC7.html)
EP (2) EP1336654A1 (cg-RX-API-DMAC7.html)
JP (2) JP3579355B2 (cg-RX-API-DMAC7.html)
AT (1) ATE305506T1 (cg-RX-API-DMAC7.html)
AU (1) AU1843200A (cg-RX-API-DMAC7.html)
CA (1) CA2353520C (cg-RX-API-DMAC7.html)
DE (1) DE69927520T2 (cg-RX-API-DMAC7.html)
DK (1) DK1137766T3 (cg-RX-API-DMAC7.html)
ES (1) ES2251248T3 (cg-RX-API-DMAC7.html)
WO (1) WO2000034459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
US20060171890A1 (en) * 2005-01-28 2006-08-03 Yeomans David C Methods for evaluating the activity of candidate agents
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2008088823A2 (en) * 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
US20110002918A1 (en) * 2009-03-06 2011-01-06 Photomedex Methods of treating diseased tissue
ES2352929B1 (es) 2009-08-14 2012-01-26 Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) Modelo humanizado de psoriasis
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2018008902A1 (ko) * 2016-07-05 2018-01-11 성균관대학교산학협력단 건선 유발 동물 모델 및 이의 용도
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191870A (en) * 1937-08-14 1940-02-27 Wayne Pump Co Liquid dispensing apparatus
US2224256A (en) * 1938-08-05 1940-12-10 Baker Chem Co J T Pharmaceutical preparation
US2297692A (en) * 1939-08-15 1942-10-06 Bendix Aviat Corp Fluid flywheel control
US2275692A (en) * 1940-04-02 1942-03-10 Sims Edward Airplane aileron
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
NL8700927A (nl) 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
IT1231727B (it) 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2070416A1 (en) * 1989-10-23 1991-04-24 Richard Ingram Polypeptide inhibitors of gamma interferon
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
CA2148907C (en) * 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6706264B1 (en) * 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
JPH08289699A (ja) * 1995-04-24 1996-11-05 Chemo Sero Therapeut Res Inst 自己免疫疾患モデル動物及びその作製方法
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US5945576A (en) 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
WO1997037679A1 (en) * 1996-04-10 1997-10-16 Board Of Trustees Of The University Of Illinois Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
WO1998016248A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2206981T3 (es) * 1997-07-17 2004-05-16 F.Hoffmann-La Roche Ag Dihomo-seco-colestanos con dos enlaces insaturados en la cadena lateral.
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
KR100764256B1 (ko) 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing

Also Published As

Publication number Publication date
US20020194631A1 (en) 2002-12-19
EP1137766A1 (en) 2001-10-04
JP4671265B2 (ja) 2011-04-13
WO2000034459A1 (en) 2000-06-15
EP1137766B1 (en) 2005-09-28
AU1843200A (en) 2000-06-26
JP2004231667A (ja) 2004-08-19
CA2353520C (en) 2006-04-25
ATE305506T1 (de) 2005-10-15
JP2002531123A (ja) 2002-09-24
ES2251248T3 (es) 2006-04-16
EP1137766A4 (en) 2002-08-14
US6410824B1 (en) 2002-06-25
DK1137766T3 (da) 2006-01-30
EP1336654A1 (en) 2003-08-20
US20030056233A1 (en) 2003-03-20
DE69927520D1 (de) 2006-02-09
DE69927520T2 (de) 2006-06-22
US9078876B2 (en) 2015-07-14
US20130071388A1 (en) 2013-03-21
US20140314756A1 (en) 2014-10-23
US9072725B2 (en) 2015-07-07
CA2353520A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
US9072725B2 (en) Method for treating psoriasis
Spahn et al. Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches
SchÖn et al. Murine psoriasis-like disorder induced by naive CD4+ T cells
RU2120802C1 (ru) Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
Murphy et al. The huPBL-SCID mouse as a means to examine human immune function in vivo
SHARROCK et al. Analysis of the alloreactive T cell repertoire in man: I. Differences in precursor frequency for cytotoxic T cell responses against allogeneic MHC molecules in unrelated individuals
Braun et al. IL‐5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8+ T lymphocytes and IFN‐γ
KR20070095949A (ko) 자가면역 장애의 치료 방법
CN110179989A (zh) 治疗狼疮的方法和组合物
Davidson et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation
Sparshott et al. CD45R CD4 T cell subset‐reconstituted nude rats: subset‐dependent survival of recipients and bi‐directional isoform switching
US6593511B1 (en) Models of chronic and acute inflammatory diseases
Swann et al. Novel immunotherapies for immune-mediated haemolytic anaemia in dogs and people
Wershil et al. The analysis of mast cell function in vivo using mast cell-deficient mice
JPH07502019A (ja) 内毒素または超抗原に誘導された毒性を治療するインターロイキン−10類似体またはアンタゴニストの使用
Govallo Immunology of pregnancy and cancer
Hook et al. Th2-dependent airway eosinophilia is regulated by preproenkephalin
HK1059633A (en) Method of treating psoriasis using anti-gamma interferon antibody
STEINSVIK et al. Interleukin‐13 and Human Immunoglobulin E Production in Severe Combined Immunodeficiency Mice Transplanted with Human Peripheral Blood Lymphocytes
JP2004315381A (ja) ナチュラルキラーT細胞のインターロイキン18による刺激を利用した免疫疾患治療薬剤および治療キット、並びにIgE産生の制御方法
US6548737B1 (en) Transgenic mice deficient in natural killer cells
González Gal-1 and lat1 as regulatory molecules in skin inflammatory diseases
Clauder Role of Interleukin-10 in the Natural Course of Epidermolysis Bullosa Acquisita
Greenwood et al. Offspring of xenogeneically-reconstituted scid/scid mice are capable of a primary xenogeneic immune response to DNP-KLH
Manetz Development of an irritancy/phenotypic analysis assay for the identification and differentiation of chemicals with the capacity to elicit irritation, IgE-mediated, or T cell-mediated hypersensitivity responses

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040715

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080723

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090723

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100723

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100723

Year of fee payment: 6

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100723

Year of fee payment: 6

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110723

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110723

Year of fee payment: 7

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110723

Year of fee payment: 7

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110723

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120723

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120723

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130723

Year of fee payment: 9

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees